Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sotagliflozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 known ✓ | P13866 | 14/20 | 1.00 |
| ▸ | SLC5A2 known ✓ | P31639 | 14/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sotagliflozin SCHEMBL17036778 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL19512410 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL10267817 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL29433934 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL19853184 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL23731430 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| SCHEMBL16234522 | 0.92 | SLC5A2 (0.85) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| SCHEMBL23077583 | 0.91 | SLC5A1 (0.83) | SLC5A1SLC5A2 | |
| SCHEMBL1036755 | 0.91 | SLC5A2 (0.83) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| SCHEMBL20787163 | 0.89 | SLC5A1 (1.00) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724042-A1 | METHOD FOR IMPROVING THE INGESTION OF A LIQUID OR VISCOUS SUBSTANCE | Ceva Santé Animale (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4719430-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4719429-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| US-12577269-B2 | Continuous process for preparing the crystalline form II of sotagliflozin | LEXICON PHARMACEUTICALS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | claimed |
| EP-4701626-A1 | AMORPHOUS OBICETRAPIB AND SGLT2 INHIBITOR COMBINATION | NewAmsterdam Pharma B.V. (NL) | 2026-03-04 | — | — | EP | claimed |
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | claimed |
| US-12551484-B2 | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | RESVERLOGIX CORP. (CA) | 2026-02-17 | — | — | US | claimed |
| EP-4691459-A1 | COMBINATION FORMULATION COMPRISING SACUBITRIL-VALSARTAN AND SGLT-2 INHIBITOR HAVING IMPROVED STABILITY AND DISSOLUTION RATE | Hanmi Pharm. Co., Ltd. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-8217156-B2 | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | claimed |
| US-20120172320-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | PATHEON INC. (CA) | 2012-07-05 | — | — | US | claimed |
| JP-2011528366-A | — | — | 2011-11-17 | — | — | JP | claimed |
| WO-2011109333-A1 | 6 -BENZYLPHENYL- 2 - SULFURTERAHYDROPYRAN-3, 4, 5 -TRIOL DERIVATIVES AS INHIBITORS OF SODIUM -GLUCOSE COTRANS PORTERS 1 AND 2 FOR USE IN DIABETIC PATIENTS | LEXICON PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20110218159-A1 | METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | LEXICON PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | claimed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | claimed |
| EP-2089361-B1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | claimed |
| US-7781577-B2 | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents | LEXICON PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | claimed |
| WO-2010009197-A1 | SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20100016422-A1 | SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2010-01-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | RXFP1, RXFP2, RXFP4 | SLC5A1 5/4885SLC5A2 6/4885ADRA2A 617/4885 |
| US-20120172320-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A1 2/4885SLC5A2 1/4885ADRA2A 557/4885 |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, PPARG | SLC5A1 2/4885SLC5A2 1/4885ADRA2A 157/4885 |
| US-20100016422-A1 | SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE | TPMT, PYGL, PNPO | SLC5A1 354/4885SLC5A2 233/4885ADRA2A 2928/4885 |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | COL1A1, COL2A1, FN1 | SLC5A1 551/4885SLC5A2 669/4885ADRA2A 1254/4885 |
| US-12551484-B2 | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | SLC5A2, SLC5A1, BRD4 | SLC5A1 2/4885SLC5A2 1/4885ADRA2A 858/4885 |
| US-12577269-B2 | Continuous process for preparing the crystalline form II of sotagliflozin | SLC5A2, SLC5A1, GCK | SLC5A1 2/4885SLC5A2 1/4885ADRA2A 539/4885 |
| US-20110218159-A1 | METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A1 2/4885SLC5A2 1/4885ADRA2A 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.